Mobius is the investment arm of BioCity Group
We invest pre-seed and seed amounts in companies based at our sites in the UK and in selected companies that have progressed through BioCity’s Accelerator programme.
Mobius will also co-invest alongside other early stage investors, including business angels and will act as a feeder to later stage funds.
- R5 Pharmaceuticals (acquired by Aesica Pharma)
- Haemostatix (acquired by Ergomed plc)
- Critical Pharmaceuticals
- BioAscent Discovery
2015 BioCity UK Life Science Start-up report
With the benefit of 10 years of data on the creation and funding of life science companies, the report suggests trends and environmental shifts that have been emerging over recent years are starting to come to a head as roles, funding models and investor preferences realign.